Cost-effectiveness of Human Papillomavirus Self-collection Intervention on Cervical Cancer Screening Uptake among Underscreened US Persons with a Cervix

被引:1
|
作者
Spees, Lisa P. [1 ,2 ,7 ]
Biddell, Caitlin B. [1 ,2 ]
Smith, Jennifer S. [2 ,3 ]
Des Marais, Andrea C. [3 ]
Hudgens, Michael G. [4 ]
Sanusi, Busola [5 ]
Jackson, Sarah [3 ]
Brewer, Noel T. [2 ,6 ]
Wheeler, Stephanie B. [1 ,2 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA
[5] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA
[6] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA
[7] Univ North Carolina Chapel Hill, Chapel Hill, NC 27599 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; CHINESE WOMEN; BREAST; KNOWLEDGE; PROGRAM;
D O I
10.1158/1055-9965.EPI-22-1267
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We evaluate the cost-effectiveness of human papillomavirus (HPV) self-collection (followed by scheduling assistance for those who were HPV thorn or inconclusive) compared with scheduling assistance only and usual care among underscreened persons with a cervix (PWAC).Methods: A decision tree analysis was used to estimate the incremental cost-effectiveness ratios (ICER), or the cost per additional PWAC screened, from the Medicaid/state and clinic perspectives. A hypothetical cohort represented 90,807 lowincome, underscreened individuals. Costs and health outcomes were derived from the MyBodyMyTest-3 randomized trial except the usual care health outcomes were derived from literature. We performed probabilistic sensitivity analyses (PSA) to evaluate model uncertainty. Results: Screening uptake was highest in the self-collection alternative (n = 65,721), followed by the scheduling assistance alternative (n = 34,003) and usual care (n = 18,161). The self collection alternative costs less and was more effective than the scheduling assistance alternative from the Medicaid/state perspective. Comparing the self-collection alternative with usual care, the ICERs were $284 per additional PWAC screened from the Medicaid/state perspective and $298 per additional PWAC screened from the clinic perspective. PSAs demonstrated that the self collection alternative was cost-effective compared with usual care at a willingness-to-pay threshold of $300 per additional PWAC screened in 66% of simulations from the Medicaid/state perspective and 58% of simulations from the clinic perspective.Conclusions: Compared with usual care and scheduling assistance, mailing HPV self-collection kits to underscreened individuals appears to be cost-effective in increasing screening uptake.Impact: This is the first analysis to demonstrate the costeffectiveness of mailed self-collection in the United States.
引用
收藏
页码:1097 / 1106
页数:10
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan
    Takamoto, Naohiro
    Aso, Shotaro
    Ishida, Risa
    Konishi, Takaaki
    Fushimi, Kiyohide
    Yasunaga, Hideo
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024,
  • [42] Impact of human papillomavirus (HPV) self-collection on subsequent cervical cancer screening completion among under-screened US women: MyBodyMyTest-3 protocol for a randomized controlled trial
    Lisa P. Spees
    Andrea C. Des Marais
    Stephanie B. Wheeler
    Michael G. Hudgens
    Sarah Doughty
    Noel T. Brewer
    Jennifer S. Smith
    Trials, 20
  • [43] Accuracy and Cost-Effectiveness of Cervical Cancer Screening by High-Risk Human Papillomavirus DNA Testing of Self-Collected Vaginal Samples
    Balasubramanian, Akhila
    Kulasingam, Shalini L.
    Baer, Atar
    Hughes, James P.
    Myers, Evan R.
    Mao, Constance
    Kiviat, Nancy B.
    Koutsky, Laura A.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2010, 14 (03) : 185 - 195
  • [44] Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
    Phua, Lee Cheng
    Choi, Horace C. W.
    Wu, Joseph
    Jit, Mark
    Low, Jeffrey
    Ng, Kwong
    Pearce, Fiona
    Hall, Cameron
    Aziz, Mohamed Ismail Abdul
    VACCINE, 2021, 39 (16) : 2262 - 2270
  • [45] THE COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS DNA TESTING FOR CERVICAL CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE
    Kingston-Riechers, J.
    VALUE IN HEALTH, 2009, 12 (03) : A44 - A44
  • [46] Evaluating implementation of HPV self-collection for cervical cancer screening among low-income, under-screened women in the US
    Miller, Elyze M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 468 - 468
  • [47] Feasibility and acceptability of self-collection of Human Papillomavirus samples for primary cervical cancer screening on the Caribbean Coast of Nicaragua: A mixed-methods study
    Mitchell, Emma McKim
    Hall, Katherine M.
    Doede, Aubrey
    Rong, Anneda
    McLean Estrada, Michelet
    Granera, Orlando Benito
    Maldonado, Francisco
    Al Kallas, Hala
    Bravo-Rodriguez, Cassandra
    Forero, Mariana
    Pokam Tchuisseu, Yolande
    Dillingham, Rebecca A.
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [48] Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Wang, Lijie
    Liu, Xianchen
    Wu, Bin
    Luo, Huiwen
    Nagata, Chie
    Mori, Rintaro
    Nakayama, Takeo
    BMC INFECTIOUS DISEASES, 2017, 17
  • [49] REDUCED CERVICAL CANCER SCREENING FREQUENCY IN HUMAN PAPILLOMAVIRUS VACCINATED, HIV-INFECTED WOMEN: A COST-EFFECTIVENESS ANALYSIS
    Cohen, Jamie
    Menzies, Nicolas A.
    Kim, Jane J.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E85 - E85
  • [50] Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial
    Cromwell, Ian
    Smith, Laurie W.
    van der Hoek, Kim
    Hedden, Lindsay
    Coldman, Andrew J.
    Cook, Darrel
    Franco, Eduardo L.
    Krajden, Mel
    Martin, Ruth
    Lee, Marette H.
    Stuart, Gavin
    van Niekerk, Dirk
    Ogilvie, Gina
    Peacock, Stuart
    CANCER MEDICINE, 2021, 10 (09): : 2996 - 3003